AtonRa Partners’s Ionis Pharmaceuticals IONS Stock Holding History

AtonRa Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$425K	Sell	8,396 -933	-10%	-$44.7K	0.85%	49
2023 Q3	$423K	Sell	9,329 -2,307	-20%	-$95.2K	0.89%	40
2023 Q2	$477K	Sell	11,636 -708	-6%	-$27.2K	0.74%	63
2023 Q1	$441K	Sell	12,344 -1,531	-11%	-$57.5K	0.64%	73
2022 Q4	$524K	Sell	13,875 -3,753	-21%	-$158K	0.67%	66
2022 Q3	$780K	Sell	17,628 -518	-3%	-$21.8K	0.77%	56
2022 Q2	$672K	Buy	+18,146	New	+$684K	0.62%	75
2021 Q2	–	Sell	-20,146	Closed	-$906K	–	115
2021 Q1	$906K	Buy	20,146 +12,329	+158%	+$688K	0.4%	94
2020 Q4	$442K	Buy	+7,817	New	+$390K	0.22%	103

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

AtonRa Partners's IONS Position: Q4 2023 in Review

AtonRa Partners reduced its Ionis Pharmaceuticals (IONS) stake by 10% in Q4 2023, selling an estimated $44.7K and leaving 8,396 shares worth $425K. The position accounts for 0.85% of the portfolio, ranked #49.

AtonRa Partners first reported a position in IONS in Q4 2020 and has held it in 9 quarters since. The position peaked at $906K in Q1 2021. 363 funds tracked by Wall St. Rank hold IONS as of Q4 2023.

AtonRa Partners held 8,396 shares of Ionis Pharmaceuticals worth $425K as of Q4 2023.
AtonRa Partners sold 933 Ionis Pharmaceuticals shares in Q4 2023, an estimated $44.7K.
Ionis Pharmaceuticals made up 0.85% of AtonRa Partners's portfolio in Q4 2023, its #49 holding.
AtonRa Partners first reported a position in Ionis Pharmaceuticals in Q4 2020 and has held it in 9 quarters since.
AtonRa Partners's Ionis Pharmaceuticals position peaked at $906K in Q1 2021.
363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.